Home › Research › Costs and economics
Cost-utility of a new psychosocial goal-setting and manualised support intervention for independence in dementia (NIDUS-Family) versus goal setting and routine care: an economic evaluation embedded within a randomised controlled trial
Isaaq A, Cooper C, Vickerstaff V, Barber JA, Walters K, Lang IA, Rapaport P, Orgeta V, Rockwood K, Butler LT, Lord K, Livingston G, et al.. The Lancet Healthy Longevity, 2025-02-17
Topic: Risk, prevention and care in population studies
Plain-language summary
Background NIDUS-Family is a psychosocial and behavioural intervention comprising six to eight sessions, delivered by non-clinical facilitators, and tailored to goals set by dyads of people with dementia and their unpaid or family carers. The intervention has been shown to be effective for attainment of personalised client goals. The current study aimed to determine whether the intervention is cost-effective. Methods In this cost-utility and cost-effectiveness analysis within a two-armed, single-masked, multisite, superiority randomised controlled trial, we recruited 302 people with dementia living in their own homes and their family carers from National Health Service community settings and social and print media across England. Participants were randomly allocated (2:1) to the NIDUS-Family intervention group or control (goal setting and routine care) group. Randomisation was blocked and site-stratified, with allocation by a remote web-based system. We calculated the probability that NIDUS-Family is cost-effective for a client with dementia based on quality-adjusted life-years from a health and social care perspective and from a societal perspective (additionally including family carer time and out-of-pocket costs), at £20 000-30 000 decision thresholds for additional quality-adjusted life-years compared with usual care over 12 months. Analyses were done using the intention-to-treat population. This study is registered with ISRCTN, ISRCTN11425138, and is completed. Findings Between April 30, 2020, and May 9, 2022, we randomly allocated 204 participants (109 [53%] women and 95 [47%] men) to the intervention group and 98 (60 [61%] women and 38 [39%] men) to the control group. 218 (72%) participants at 6 months and 178 (59%) at 12 months provided cost data. At both a £20 000 and £30 000 decision threshold, there was an 89% probability that NIDUS-Family was cost-effective compared with usual care from a health and social care perspective, and an 87% probability from a societal perspective. Intervention participants accrued on average £8934 (37%) less in costs than control participants (95% CI -£59 460 to £41 592). Interpretation NIDUS-Family is the first personalised care and support intervention to show both cost-effectiveness from the perspective of the quality of life of people with dementia as well as clinical effectiveness and should therefore be part of routine dementia care. Funding Alzheimer's Society.
What this study adds
Evidence grade: High
The record lists 302 participants. It addresses cost-effectiveness of a psychosocial and behavioural intervention for goal attainment, not a cure or prevention of Alzheimer's disease. Reported effect size: 89% probability of cost-effectiveness; mean cost saving £8,934 (37%), CI includes zero.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Isaaq, A., Cooper, C., Vickerstaff, V., Barber, J. A., Walters, K., Lang, I. A., et al. (2025). Cost-utility of a new psychosocial goal-setting and manualised support intervention for independence in dementia (NIDUS-Family) versus goal setting and routine care: an economic evaluation embedded within a randomised controlled trial. The Lancet Healthy Longevity. https://doi.org/10.1016/j.lanhl.2024.100676
Vancouver
Isaaq A, Cooper C, Vickerstaff V, Barber JA, Walters K, Lang IA, et al. Cost-utility of a new psychosocial goal-setting and manualised support intervention for independence in dementia (NIDUS-Family) versus goal setting and routine care: an economic evaluation embedded within a randomised controlled trial. The Lancet Healthy Longevity. 2025. doi:10.1016/j.lanhl.2024.100676. PMID: 39978389.
BibTeX
@article{isaaq2025-39978389,
author = {Isaaq, A. and Cooper, C. and Vickerstaff, V. and Barber, J. A. and Walters, K. and Lang, I. A. and Rapaport, P. and Orgeta, V. and Rockwood, K. and Butler, L. T. and Lord, K. and Livingston, G. and others},
title = {{Cost-utility of a new psychosocial goal-setting and manualised support intervention for independence in dementia (NIDUS-Family) versus goal setting and routine care: an economic evaluation embedded within a randomised controlled trial}},
journal = {The Lancet Healthy Longevity},
year = {2025},
doi = {10.1016/j.lanhl.2024.100676},
pmid = {39978389},
url = {https://doi.org/10.1016/j.lanhl.2024.100676}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We calculated the probability that NIDUS-Family is cost-effective for a client with dementia based on quality-adjusted life-years from a health and social care perspective and from a societal perspective (additionally including family carer time and out-of-pocket costs), at £20 000-30 000 decision thresholds for additional quality-adjusted life-years compared with usual care over 12 months.
- At both a £20 000 and £30 000 decision threshold, there was an 89% probability that NIDUS-Family was cost-effective compared with usual care from a health and social care perspective, and an 87% probability from a societal perspective.
Why it matters
In this economic evaluation within a randomized controlled trial of 302 people with dementia and their family carers, there was an 89% probability that NIDUS-Family was cost-effective compared with usual care from a health and social care perspective at both £20,000 and £30,000 decision thresholds, and an 87% probability from a societal perspective. It addresses cost-effectiveness of a psychosocial and behavioural intervention for goal attainment, not a cure or prevention of Alzheimer's disease.
New to this subject? Start with our plain-English guide: Costs & economics →
Study details
- Study designRCT
- Participants302
- Effect size89% probability of cost-effectiveness; mean cost saving £8,934 (37%), CI includes zero
- Evidence strengthHigh
How this study scored 68/100
Published in a leading specialty journal, and it is a randomized controlled trial. We have no data on senior author's track record and free to read, so those were left out: it earned 64 of the 94 points we could judge it on, which is 68 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (The Lancet Healthy Longevity) |
| Journal's citation record | 1 / 4 | The Lancet Healthy Longevity: journal h-index 78 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 302 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 2 / 7 | Cited 12 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 10.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 12 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 9 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39978389) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 64 / 94 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 64 of the 94 points we could judge it on is 68 out of 100. |
| Total | 68 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Costs and economics from nearby years
Also tagged “nursing”
995 studies in the library carry the topic tag “nursing”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 995 tagged studies.